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Key points 
 
Question: What are the characteristics and findings of pre-approval and post-approval trials of 
drugs granted FDA Accelerated Approval between 2009 and 2013? 
 
Findings: Clinical trials conducted before and after Accelerated Approval have similar design 
characteristics such as lack of blinding, randomization, and comparator groups. While most 
post-approval confirmatory studies showed some benefit, they rely on surrogate measures 
rather than clinical outcomes. 
 
Meaning: Although many drugs granted Accelerated Approval by the FDA from 2009-2013 
had had their efficacy confirmed in post-approval trials, there may be limitations in the study 
designs and endpoints used. 
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Abstract 
Importance: Drugs treating serious conditions can receive US Food and Drug 
Administration (FDA) Accelerated Approval based on showing an effect in surrogate 
measures that are only reasonably likely to predict clinical benefit. Confirmatory trials are 
then required to determine whether these effects translate to clinical improvements.  
Objective: To characterize pre-approval and confirmatory clinical trials of drugs granted 
Accelerated Approval.  
Design and Setting: Publicly available FDA documents were surveyed to evaluate the pre-
approval trials leading to Accelerated Approval between 2009 and 2013. Information on the 
status and findings of required confirmatory studies was extracted from the FDA’s database 
of postmarketing requirements and commitments, ClinicalTrials.gov, and matched 
publications. End date of follow up was 7 April 2017. 
Exposure: Granting of Accelerated Approval.  
Main Outcomes and Measures: Characteristics of pre-approval and confirmatory studies 
were compared in terms of study design features (randomization, blinding, comparator, 
primary endpoint) and indications. Subsequent regulatory decisions and estimated time 
between Accelerated Approval and fulfillment of regulatory requirements were reviewed.  
Results: FDA granted Accelerated Approval to 22 drugs for 24 indications in the study 
period. At a minimum 3 years of follow-up, 19 of 38 required confirmatory studies were 
completed (50%). The proportion of studies with randomized designs did not differ before 
and after Accelerated Approval (16%, 95% confidence interval [CI]: -15%-46%; P=0.31). 
Post-approval requirements were completed and demonstrated efficacy in 10 indications 
(42%) on the basis of trials that evaluated surrogate measures alone. Among the 14 
indications (58%) that had not yet completed requirements, confirmatory studies failed to 
demonstrate clinical benefit in 2 (8%) indications; were terminated in 2 (8%); and were 
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delayed by more than one year in 3 (13%) with no regulatory action. Studies were 
progressing according to target timelines for the remaining 7 indications (29%). Clinical 
benefit had not yet been confirmed for 7 indications that had been initially approved 5 or 
more years prior.  
Conclusions and Relevance: Many drugs recently granted Accelerated Approval had had their 
efficacy confirmed in post-approval trials, although confirmatory trials have similar design 
elements to pre-approval trials, including reliance on surrogate measures as outcomes. Delays 
in completing post-approval confirmatory trials persisted for a minority of drugs.  
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Introduction 
The US Food and Drug Administration (FDA) has several pathways aimed at 
expediting the development and approval of drugs that address serious or life-threatening 
conditions.1 The Accelerated Approval pathway permits the FDA to grant marketing 
authorization on the basis of surrogate measures—biomarkers, laboratory values, or other 
physical measures that may serve as indicators of clinical outcomes such as symptom control 
or mortality—that are only “reasonably likely” to predict clinical benefit.2 Once Accelerated 
Approval drugs are granted marketing authorization, the FDA requires that the sponsors 
complete confirmatory trials to describe and verify clinical efficacy.3 When these 
requirements are fulfilled, the drug’s label may be updated to account for the new 
information.  
While special pathways like Accelerated Approval can be highly effective in 
facilitating the testing of certain new drugs,4,5 they have also been a source of controversy. 
Drugs approved via expedited pathways may have greater safety risks to patients.6,7 There is 
also uncertainty about whether observed effects on surrogate measures will materialize into 
clinical improvements.8 In a review of drugs approved by the FDA between 2005 and 2012 
on the basis of limited evidence, only a minority showed efficacy in controlled trials in the 
post-approval period.9 Confirmatory trials evaluating the clinical benefit of drugs in the 
Accelerated Approval pathway can also be substantially delayed.10 In a previous evaluation of 
Accelerated Approval of oncology products, clinical benefit was demonstrated in 
confirmatory studies for approximately half of new indications,11 but drugs granted 
Accelerated Approval quickly become standard of care despite the tenuous evidence on 
which they were approved.12  
The implementation of the Accelerated Approval pathway in recent years has not 
been characterized. We sought to compare the evidence gathered on qualifying drugs before 
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and after approval, including the extent to which confirmatory studies were completed and 
determined whether they demonstrated clinically meaningful benefits.13 We also reviewed the 
time between Accelerated Approval and fulfillment of post-approval requirements. 
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Methods 
Sample Identification 
Two investigators (H.N., K.R.S.) reviewed publicly available FDA documents 
(“CDER Drug and Biologic Accelerated Approvals as of 30 June 2016” and “Novel Drug 
Approvals” for 2011-2013) to identify drugs granted Accelerated Approval over 5 years 
between 1 January 2009 and 31 December 2013.1 The CDER Drug and Biologic Accelerated 
Approvals list is compiled by the FDA’s Center for Drug Evaluation and Research. The 
Novel Drug Approvals report is an annual catalog of approved new molecular entities. Our 
sample included drugs that received Accelerated Approval as new therapeutic agents and as 
supplemental approvals (products already approved for other indications). Drugs that 
received original marketing authorization prior to 2009 were also included if they received a 
supplemental Accelerated Approval for a new indication during our study period. 
Accelerated Approvals for new formulations (e.g., tablet vs. injection) of already-approved 
agents were excluded (n=1). We confirmed the consistency of our sample with a previously 
published report on FDA approvals.14 Our study period ended in 2013, allowing at least 3 
years for the completion and publication of confirmatory clinical studies, and a median of 5 
years.  
 
Identification of Pre-approval Studies 
We identified and characterized the clinical studies underlying Accelerated Approval. 
For all drugs in our sample, we examined medical review reports and product labels from the 
Drugs@FDA database to identify pre-approval studies that established the drug’s efficacy. 
Drugs@FDA is a publicly available database of all FDA-approved products and contains the 
approval history for each product, including links to communications from the FDA to the 
sponsor, and product label updates.15 When available, we used the medical review reports to 
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gather information about pre-approval trial characteristics. Medical review reports provide a 
comprehensive overview of drugs’ efficacy and safety. When medical reviews were not 
available (as can be the case for supplemental approvals), we used the product labels that 
describe the key clinical studies that supported the Accelerated Approval for a new 
indication.  
 
Identification of Post-approval Confirmatory Studies 
We systematically examined the FDA’s approval letters available on the Drugs@FDA 
database to identify the confirmatory study requirements at the time of Accelerated 
Approval.16 We excluded postmarketing study requirements focusing on safety evaluations 
alone under FDAAA Section 505(o)(3) regulations.17 We relied on information reported in 
product labels and FDA’s approval letters to summarize how the FDA characterized the 
main limitation of the available data at the time of Accelerated Approval and whether 
required postmarketing studies assessed efficacy, safety, or long-term follow-up.  
We then reviewed two sources to determine the status of post-approval study 
requirements. First, we first searched the FDA’s publicly available database of postmarketing 
requirements and commitments.18 This database specifies the clinical studies that satisfy 
postmarketing requirements and commitments to gather additional information about a 
product's safety, efficacy, or optimal use. For the agents with confirmatory studies, we noted 
whether the study was ongoing, delayed, submitted, or fulfilled. Consistent with previous 
reports,19,20 a substantial proportion (n=18, 47%) of indications did not have matching 
postmarketing requirements listed in the FDA database. Second, we screened 
ClinicalTrials.gov for all confirmatory study requirements. ClinicalTrials.gov is a publicly 
available clinical study registry and results database developed and maintained by the U.S. 
National Library of Medicine.3 Since 2007, Section 801 of the FDA Amendments Act has 
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required the registration of clinical studies subject to FDA regulation, including studies that 
satisfy postmarketing requirements. For each registered study, ClinicalTrials.gov specifies the 
status (e.g., still recruiting, ongoing but no longer recruiting, completed), as well as start and 
end date. We noted whether the confirmatory study was completed or ongoing per specified 
timelines in the FDA’s approval letters. Studies were considered to be delayed if the 
estimated primary completion date in ClinicalTrials.gov was at least one year later than that 
specified in the FDA approval letters. When there was a discrepancy between the FDA’s 
public database and ClinicalTrials.gov, we relied on ClinicalTrials.gov to determine the status 
of post-approval study requirements.  
 
Identification of Published Reports  
Using a step-wise approach,21,22 we searched for the published reports of completed 
confirmatory studies. First, we checked if there was a publication link available on the 
ClinicalTrials.gov file for each study. ClinicalTrials.gov periodically searches Pubmed to 
identify corresponding publications; investigators of studies can also add publication links 
manually. Second, we searched Pubmed using the ClinicalTrials.gov identification number. 
Third, we searched Pubmed and Google using the name of the principal investigator of the 
study (when available in ClinicalTrials.gov) in combination with the condition and drug name. 
Identified publications were matched to the corresponding postmarketing study based on the 
condition, comparator(s), enrollment, and primary and secondary outcome measures.  
 
Data Extraction 
We extracted the following data from each pre-approval and confirmatory study: 
design (randomized vs. nonrandomized), indication, comparator(s), participant enrollment, 
and primary endpoint. Comparators were classified as active (in trials comparing drugs A vs. 
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B), add-on (in trials comparing drugs A + B vs. drug B alone), placebo, or none. Drugs 
tested in single-arm trials were classified as having no comparators. We also noted the type 
of blinding (double-blinded vs. open-label). Study findings were summarized in terms of the 
specified primary endpoint. In confirmatory studies, we assessed whether the findings 
demonstrated verification of clinical benefit. All data extraction was performed 
independently by two investigators (H.N., K.R.S.) and disagreements resolved by consensus.  
 
Assessment of Regulatory Outcomes  
To determine whether drugs granted Accelerated Approvals later had their labels 
updated, we examined changes to product labels and the accompanying regulatory letters. 
The FDA’s correspondence with product sponsors on topics related to the approval and 
changes in status of their products is publicly available on the Drugs@FDA database. We 
systematically screened the regulatory letters for either confirmation of the fulfillment of the 
requirements,23 or the lack of regulatory action as of the end of our data collection (April 7, 
2017). We estimated the time between the granting of Accelerated Approval and the 
associated label update.  
 
Statistical Analysis 
Using descriptive statistics, we characterized the clinical studies supporting the 
Accelerated Approval of drugs included in our sample. Next, Wilcoxon-Mann-Whitney and 
t-tests were used, as appropriate, to examine differences in study features between pre-
approval and confirmatory studies, including enrollment, design, comparator(s), and primary 
endpoints. Two-tailed p values <0.008 were considered statistically significant, taking into 
account the 6 comparisons made between the two groups of studies. All analyses were 
performed using STATA (version 14, Stata Corp, College Station, Texas, USA).  
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Results 
Between 2009 and 2013, the FDA granted Accelerated Approval to 22 drugs for 24 
indications, with two products granted the designation for two indications (Table 1). 
Fourteen approvals were for novel therapeutic agents and 10 were for supplemental 
indications for previously-approved drugs. Cancer accounted for 19 of the indications. The 
remaining covered a range of conditions including transfusion and non-transfusion 
dependent iron overload, multi-drug resistant tuberculosis, and Hunter syndrome.  
 
Features of Pre-approval Studies 
Thirty pre-approval studies supported the 24 indications of interest. Twelve studies 
were randomized (40%) and 6 were double-blinded (20%) (Table 2). A minority of pre-
approval studies used placebo controls (n=6, 20%), 2 (7%) used an active comparator, 
another 2 evaluated the active agent as an add-on to a standard treatment regimen, and more 
than half had no comparators (n=18, 60 %). Eight studies (27%) included fewer than 100 
participants and 20 (67%) included fewer than 200. The median number of participants 
enrolled in the pre-approval studies was 132 (interquartile range [IQR]: 89-224).  
The most common surrogate measure used in the pre-approval studies was a measure 
of disease response, such as response rate (n=21), consistent with the fact that most were 
oncology drugs. Other surrogate measures included time-to-event outcomes (e.g., time-to-
sputum culture conversion, progression-free survival), change in baseline biomarker levels 
(e.g., liver iron concentration), and acceptable safety (Table 2).  
Nonrandomized, noncomparative single-arm studies formed the exclusive basis of 
Accelerated Approval for 14 indications (47%), and pre-approval studies with fewer than 200 
participants supported the Accelerated Approval of 12 indications (40%).  
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Status of Required Post-approval Confirmatory Studies 
At the time of Accelerated Approval, the FDA labels emphasized the limitations of 
the available data (Figure). The majority of labels highlighted the lack of evidence 
demonstrating an improvement in disease-related symptoms or survival (n=19, 79%) 
(eTable 1). To address these limitations, the FDA required the completion of 38 post-
approval confirmatory trials for the 24 indications. Twenty-five (66%) examined clinical 
efficacy, 7 (18%) evaluated longer follow-up and 6 (16%) focused on safety (Figure). 
Most requirements were for randomized controlled trials (n=25, 66%). The 
remaining 13 requirements (34%) were for single-arm studies (eTable 2). Prespecified 
primary endpoints were reported in approximately one-third (n=13, 34%) of the required 
confirmatory studies from publicly available documents. Among this sample, the most 
common prespecified endpoint was progression-free survival (n=9), followed by overall 
survival (n=3) (eTable 2).  
Nineteen (50%) confirmatory study requirements had been fulfilled as of April 7, 
2017. Of the remaining 19, 11 were underway according to planned timelines, 6 were 
reported to be delayed by more than 12 months, and 2 had been terminated (Figure). In 
most cases, recruitment challenges were cited as the primary reason for reported delays 
(eTable 2).  
 
Features of Completed and Published Post-approval Confirmatory Studies 
Published reports were available for 18 out of 20 completed confirmatory studies. 
Ten (56%) of the completed and published post-approval confirmatory studies were 
randomized and 1 (6%) was double-blinded (Table 3). One study included a placebo 
comparator, 2 evaluated the Accelerated Approval agent as an add-on to a standard 
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treatment regimen, 7 (39%) had active comparators, and 8 (44%) had no comparators 
(single-arm). The majority of completed confirmatory studies included more than 100 
participants, while the median number of participants enrolled in post-approval studies was 
345 (IQR: 111-619).  
Surrogate measures were the primary endpoints in 17 of the 18 studies. Disease 
response was the most common surrogate (n=9, 50%), followed by progression-free survival 
(n=6, 33%) and pharmacokinetic measures (n=2, 11%). The only confirmatory study that 
did not test a surrogate had co-primary endpoints of overall survival and progression-free 
survival. 
Most completed post-approval studies showed that the drug had some benefit on the 
surrogate measure (n=15, 83%), including 2 trials that evaluated pharmacokinetics (Table 3). 
The remaining 3 studies (18%) either failed to demonstrate efficacy or were terminated early. 
In a randomized controlled trial, the addition of bevacizumab to radiotherapy improved 
progression-free survival, but did not extend overall survival in patients with glioblastoma 
multiforme.18 Lapatinib combined with taxane showed shorter progression-free survival 
compared with trastuzumab as first-line therapy for HER2-positive metastatic breast 
cancer.24 One of the required confirmatory studies of ponatinib among previously untreated 
patients with chronic myeloid leukemia was terminated early due to higher rates of arterial 
occlusive events observed in patients receiving ponatinib in other trials.25  
Table 4 shows the comparison of pre-approval and published post-approval trial 
characteristics. The proportion with randomized designs was not statistically significantly 
different before and after Accelerated Approval (16%, 95% CI -15% to 46%; P=0.305). The 
confirmatory studies were more likely to use the surrogate measure of progression-free 
survival as the primary trial endpoint (36%, 95% CI 15% to 56%; P=0.001).  
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Regulatory Outcomes for Accelerated Approval Drugs 
Of 24 indications treated by the drugs granted Accelerated Approval between 2009 
and 2013, 10 (42%) fulfilled their postmarketing requirements and had their labels updated 
(Figure). All of the label updates were based on postmarketing studies evaluating surrogate 
measures. Label changes were supported by response rate in 6 (25%) indications, 
progression-free survival in 3 (13%) and changes in subependymal giant cell astrocytoma 
volume in 1 (4%) case. The completed confirmatory studies had no comparators in 4 cases, 
including 2 confirmatory trials that were single-arm open-label extensions of pre-approval 
randomized trials.  
Among the remaining 14 indications with no label updates, confirmatory studies 
failed to demonstrate clinical benefit in 2 (8%) indications and studies were terminated in 2 
(8%) indications. Studies for the remaining 10 indications remained ongoing, with 7 
progressing according to target timelines and 3 reported to be delayed by more than one year.  
Figure shows the duration of time elapsed between Accelerated Approval and 
follow-up actions by our study end date. Time from Accelerated Approval to fulfillment of 
requirements ranged from 1.3 years to 5.3 years among the 10 indications for which the 
requirements were fulfilled. Time elapsed since Accelerated Approval was 5 years or more 
for 7 indications.  
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Discussion 
The clinical trial evidence on therapeutic agents granted Accelerated Approval by the 
FDA between 2009 and 2013 shows that 14 of 24 indications entered the market on the 
basis of single-arm studies enrolling small numbers of patients. After approval, half of 
required confirmatory studies were completed within at least 3 years on the market. The 
quality and quantity of postmarketing studies required by the FDA to confirm clinical benefit 
varied widely across indications. There were few statistically detectable differences in the key 
design features of trials conducted before and after approval. Nonrandomized studies were 
common in the Accelerated Approval pathway both before and after market entry. While the 
majority of completed studies showed positive results in the postmarketing period, all 
completed confirmatory studies demonstrating drug benefit evaluated surrogate measures of 
disease activity rather than clinical outcomes.  
Drugs granted Accelerated Approval receive market authorization on the basis of 
fewer studies, smaller patient populations, shorter follow-up and less established surrogate 
measures than drugs approved via the traditional pathway.26 In these cases, post-approval 
confirmation of clinical benefit is essential. For the 10 Accelerated Approvals between 2009 
and 2013 that have since had their requirements fulfilled and labels updated, all of which 
were for cancer indications, the studies used to confirm clinical benefit tested surrogate 
measures. FDA senior scientists consider overall survival to be the most dependable 
endpoint in clinical trials of cancer drugs.27 Yet, overall survival was among the prespecified 
primary endpoints in only a small fraction of required confirmatory studies. Disease response 
was the most common endpoint in post-approval trials, and although disease response may 
be an appropriate surrogate measure in hematological malignancies, its adequacy depends on 
several factors such as the magnitude and duration of effect.28 In the remaining cases, 
postmarketing requirements were fulfilled based on improvements in progression-free 
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survival, which may not be a statistically validated surrogate for survival in all settings.28 Our 
findings are aligned with previous research showing that cancer drugs approved on the basis 
of surrogate measures may not show survival benefit in the postmarketing period.29 
Another finding from our data is the slow progression of some post-approval studies. 
A recent Government Accountability Office report criticized the FDA’s oversight of drugs 
approved on the basis of surrogate measures.19 Although the fulfillment of postmarketing 
commitments and requirements improved overall from 2009 to 2011, the number of studies 
with delays doubled during the same period.20 For 14 of 24 indications granted Accelerated 
Approval from 2009 to 2013, results from required confirmatory studies were not available 
after several years of follow-up, and 8 of 19 incomplete confirmatory studies were either 
terminated or delayed by more than one year.  
Confirmatory studies failed to demonstrate clinical benefit in 2 indications granted 
Accelerated Approval between 2009 and 2013. According to the Code of Federal 
Regulations, the FDA may withdraw a therapeutic agent if confirmatory studies fail to verify 
its clinical benefit. However, according to publicly available documents, the FDA has neither 
rescinded its approval nor imposed additional requirements for these 2 indications. 
Historically, the FDA has withdrawn an indication only once during the 25 years since the 
Accelerated Approval pathway was established. For bevacizumab (Avastin), which received 
Accelerated Approval in 2008 on the basis of progression-free survival for patients with 
metastatic breast cancer, the FDA later rescinded its approval for this indication after 
multiple postmarketing trials revealed no improvement in survival and increased toxicity.30  
This study has several limitations. First, it was limited to the pre-approval and 
confirmatory studies presented to the FDA. There may be other studies that evaluated the 
clinical benefit of therapeutic agents granted Accelerated Approvals, but if those studies were 
rigorous and reflected strongly on the utility of the product, it is likely that the manufacturer 
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would have presented them to the FDA and used them to contribute to any label updates.31 
When safety-related postmarketing requirements under FDAAA Section 505(o)(3) generated 
efficacy data, we captured this information if it was used to inform label changes. Our 
findings are supported by another large investigation of drugs approved on the basis of a 
surrogate measures or single trials, which showed that post-approval studies rarely evaluate 
efficacy using clinical outcomes.32 Second, we did not examine the adequacy of the 
confirmatory studies in addressing questions about the drugs that the FDA considered to be 
unresolved, because such insights are not available from the FDA documents. 
Third, we examined a recent cohort of approvals, and the minimum 3 years of 
follow-up may not be adequate for completing some post-approval studies. However, our 
findings were consistent with a previous review of Accelerated Approvals in oncology, which 
showed a similar proportion of incomplete confirmatory studies.10 Restricting our sample to 
Accelerated Approvals between 2009 and 2012 did not change our findings (data not shown). 
Fourth, our assessment focused on the trials’ sample size, comparators, endpoints, and 
findings. Data on other important characteristics, including risk of bias and trial duration, 
were not consistently reported in FDA documents and published reports. Fifth, the 
comparisons between pre-approval and post-approval study characteristics may be 
underpowered to detect statistically significant differences.  
   
Conclusions 
Many drugs recently granted Accelerated Approval between 2009 and 2013 have had 
their efficacy confirmed in post-approval trials, although confirmatory trials have similar 
design elements to pre-approval trials, including reliance on surrogate measures. Delays in 
completing post-approval confirmatory trials were observed for a minority of drugs. 
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Figure legends 
 
Figure 1. Key data limitations at the time of Accelerated Approval, objectives of postmarketing 
requirements, and timelines for completion. 
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Tables 
 
Table 1. Drugs and Accelerated Approval Indications, 2009-2013. 
Agent Year 
approved 
Indication at the time of Accelerated Approval 
Bevacizumab 2009 Treatment of glioblastoma, as a single agent for patients with progressive disease 
following prior therapy 
Ofatumumab 2009 Treatment of patients with CLL refractory to fludarabine and alemtuzumab 
Pralatrexate  2009 Treatment of patients with relapsed or refractory PTCL 
Dasatinib 2010 Treatment of newly diagnosed adults with Ph+ CML in chronic phase  
Everolimus 2010 Treatment of SEGA associated with TS who require therapeutic intervention but are 
not candidates for curative surgical resection  
Lapatinib 2010 In combination with letrozole for the treatment of postmenopausal women with 
hormone receptor positive metastatic breast cancer that overexpresses the HER2 
receptor for whom hormonal therapy is indicated 
Nilotinib 2010 Treatment of newly diagnosed adult patients with Ph+ CML in chronic phase 
Brentuximab vedotin 2011 The treatment of patients with Hodgkin lymphoma after failure of ASCT or after 
failure of at least two prior multi-agent chemotherapy regimens in patients who are 
not ASCT candidates  
Brentuximab vedotin 2011 The treatment of patients with systemic anaplastic large cell lymphoma after failure 
of at least one prior multi-agent chemotherapy regimen  
Crizotinib 2011 Treatment of patients with locally advanced or metastatic NSCLC that is ALK-
positive as detected by an FDA-approved test 
Deferiprone 2011 Treatment of patients with transfusional iron overload due to thalassemia syndromes 
when current chelation therapy is inadequate  
Hydroxyprogesterone 
caproate  
2011 To reduce the risk of preterm birth in women with a singleton pregnancy who have a 
history of singleton spontaneous preterm birth 
Romidepsin 2011 Treatment of PTCL in patients who have received at least one prior therapy  
Bedaquiline 2012 Indicated as part of combination therapy in adults (≥ 18 years) with pulmonary 
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MDR-TB 
Carfilzomib 2012 Treatment of patients with multiple myeloma who have received at least two prior 
therapies including bortezomib and an immunomodulatory agent and have 
demonstrated disease progression on or within 60 days of completion of the last 
therapy  
Everolimus 2012 Treatment of adults with renal angiomyolipoma and TSC, not requiring immediate 
surgery  
Omacetaxine 
mepesuccinate  
2012 Treatment of adult patients with chronic or accelerated phase CML with resistance 
and/or intolerance to two or more TKIs  
Ponatinib 2012 Treatment of adult patients with chronic phase, accelerated phase, or blast phase 
CML that is resistant or intolerant to prior TKI therapy or Ph+ALL that is resistant 
or intolerant to prior TKI therapy 
Vincristine sulfate 
liposome 
2012 Treatment of adult patients with Ph- ALL in second or greater relapse or whose 
disease has progressed following two or more anti-leukemia therapies  
Pomalidomide 2013 Patients with multiple myeloma who have received at least two prior therapies 
including lenalidomide and bortezomib and have demonstrated disease progression 
on or within 60 days of completion of the last therapy  
Ibrutinib 2013 Treatment of patients with MCL who have received at least one prior therapy  
Deferasirox 2013 Treatment of chronic iron overload in patients 10 years of age and older with non-
transfusion dependent thalassemia syndromes and with a LIC of at least 5 mg Fe per 
gram of dry weight and a serum ferritin greater than 300 mcg/L 
Idursulfase 2013 Patients between 16 months to 5 years of age with Hunter syndrome  
(Mucopolysaccharidosis II)  
Pertuzumab 2013 Use in combination with trastuzumab and docetaxel as neoadjuvant treatment of 
patients with HER2-positive, locally advanced, inflammatory, or early stage breast 
cancer (either greater than 2 cm in diameter or node positive) as part of a complete 
treatment regimen for early breast cancer  
ALK: anaplastic lymphoma kinase; ALL: acute lymphoblastic leukemia; ASCT: autologous stem cell transplant; CLL: 
chronic lymphocytic leukemia; CML: chronic myeloid leukemia; LIC: liver iron concentration; MCL: mantle cell 
lymphoma; MDR-TB: multi-drug resistant tuberculosis; NSCLC: non-small cell lung cancer; Ph+: Philadelphia 
chromosome-positive; Ph-: Philadelphia chromosome-negative; PTCL: peripheral T-cell lymphoma; SEGA: 
subependymal giant cell astrocytoma; TKI: tyrosine kinase inhibitors; TS: tuberous sclerosis; TSC: tuberous sclerosis 
complex.  
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Table 2. Characteristics of pre-approval studies of drugs receiving Accelerated Approval.  
Agent Participant population Design Comparators Enrollment Primary endpoint 
Bevacizumab 
 
Glioblastoma after prior 
therapy 
Randomized non-
comparative study 
None 
 
85 
 
Objective response rate 
Glioblastoma after prior 
therapy 
Single-arm trial None 56 Objective response rate 
Pralatrexate PTCL after prior therapy Single-arm trial None 115 Overall response rate 
Ofatumumab CLL after prior therapy Single-arm trial None 154 Objective response rate 
Lapatinib Postmenopausal women with 
HER2-positive metastatic 
breast cancer with no prior 
therapy for whom hormonal 
therapy is indicated 
Placebo-controlled, 
double-blind 
randomized trial 
Arm 1: lapatinib + letrozole  
Arm 2: letrozole + placebo 
219 PFS 
Nilotinib Newly diagnosed Ph+ CP 
CML 
Active-comparator, 
open-label randomized 
trial 
Arm 1: nilotinib  
Arm 2: imatinib 
846 Major molecular response 
Dasatinib Newly diagnosed CP CML Active-comparator, 
open-label randomized 
trial 
Arm 1: dasatinib  
Arm 2: imatinib 
519 Complete cytogenetic 
response 
Everolimusa SEGA associated with TS Single-arm trial None 28  Change in SEGA volume 
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Hydroxy-
progesterone 
caproate 
Women with previous 
singleton spontaneous 
preterm birth 
Placebo-controlled, 
double-blind 
randomized trial 
Arm 1: hydroxyprogesterone  
Arm 2: placebo 
463 Proportion of deliveries at 
<37 weeks of gestation 
Romidepsin 
 
PTCL after one or more 
prior therapy 
Single-arm trial None 131 Complete response rate 
PTCL after one or more 
prior therapy 
Single-arm trial None 47 Complete response rate 
Brentuximab 
vedotinb 
Hodgkin lymphoma after  
ASCT of after failure of at 
least two prior multi-agent 
chemotherapy regimens in 
patients who are not ASCT 
candidates 
Single-arm trial None 102 Objective response rate 
Brentuximab 
vedotinc 
Systemic anaplastic large cell 
lymphoma after prior therapy 
Single-arm trial None 58 Objective response rate 
Crizotinib 
 
Locally advanced or 
metastatic ALK+ NSCLC 
after prior therapy 
Single-arm trial 
 
 
None 
 
 
136 
 
 
Objective response rate 
 
Locally advanced or 
metastatic ALK+ NSCLC 
Single-arm trial None 119 Objective response rate 
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after prior therapy 
Deferiprone Transfusion-dependent iron 
overload after prior therapy 
Single-arm trial 
(pooled analysis of 12 
studies) 
None 236 ≥20% decline in ferritin 
Everolimusd Renal angiomyolipoma as a 
feature of TSC or sporadic 
lymphangio-leimyomatosis 
Placebo-controlled, 
double-blind 
randomized trial 
Arm 1: everolimus 
Arm 2: placebo 
118 Angiomyolipoma response 
rate 
Carfilzomib Multiple myeloma after two 
or more prior therapies 
Single-arm trial None 266 Overall response rate 
Vincristine sulfate 
liposome 
Ph- ALL after two or more 
prior therapies 
Single-arm trial None 65 Complete remission and 
complete remission with 
incomplete blood count 
recovery 
Omacetaxine 
mepessucinate 
CP and AP CML after two or 
more TKIs  
Single-arm trial  
(pooled analysis of 2 
studies) 
None 111 Major cytogenetic and 
hematologic response  
Ponatinib CP, AP and BP CML and 
Ph+ ALL after prior TKI 
Single-arm trial None 449 Major cytogenetic and 
hematologic response  
Bedaquiline 
 
Newly diagnosed patients 
with MDR-TB 
Placebo-controlled, 
double-blind 
Arm 1: bedaquiline + other drugs used to 
treat MDR-TB  
160 Proportion with sputum 
culture conversion 
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randomized trial Arm 2: placebo + other drugs used to 
treat MDR-TB 
 
 Other drugs: thionamide, kanamycin, pyrazinamide, 
ofloxacin, and cycloserine/terizidone or available 
alternative 
Newly diagnosed patients 
with MDR-TB 
Placebo-controlled, 
double-blind 
randomized trial 
Arm 1: bedaquiline + other drugs used to 
treat MDR-TB 
Arm 2: placebo + other drugs used to 
treat MDR-TB 
47 Proportion with sputum 
culture conversion 
Deferasirox 
 
Non-transfusion-dependent 
thalassemia syndromes and 
iron overload 
Placebo-controlled, 
double-blind 
randomized trial 
Arm 1: deferasirox 5 mg/kg/day 
Arm 2: deferasirox 10 mg/kg/day 
Arm 3: placebo 
166 Mean change in liver iron 
concentration from baseline 
(mg Fe/g dry weight) 
Non-transfusion-dependent 
thalassemia syndromes and 
iron overload 
Single-arm extension of 
randomized trial 
None 133 Proportion achieving liver 
iron concentration <5 mg 
Fe/g dry weight 
Pomalidomide Refractory multiple myeloma 
after receiving lenalidomide 
and bortezomib 
Randomized non-
comparative study 
Arm 1: pomalidomide 
Arm 2: pomalidomide + low-dose 
dexamethasone 
221 Overall response rate 
Idursulfase Patients with Hunter Single-arm trial None 28 Adverse reactions (safety 
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syndrome between ages of 16 
months and 7.5 years 
trial) 
Pertuzumab 
 
Patients with operable, locally 
advanced, or inflammatory 
HER2-positive breast cancer 
Add-on comparator, 
open-label randomized 
controlled trial 
Arm 1: pertuzumab + trastuzumab + 
docetaxel 
Arm 2: trastuzumab + docetaxel 
417 Pathological complete 
response rate 
Patients with operable, locally 
advanced, or inflammatory 
HER2-positive breast cancer 
Add-on comparator, 
open-label randomized 
controlled trial 
Arm 1: Pertuzumab + trastuzumab + 
FEC followed by pertuzumab + 
trastuzumab + docetaxel 
Arm 2: pertuzumab + trastuzumab + 
docetaxel following FEC  
Arm 3: pertuzumab + TCH 
225  Cardiac safety 
(Pathological complete 
response rate is secondary 
endpoint) 
Ibrutinib Mantle-cell lymphoma after 
one or more therapy 
Single-arm trial None 111 Overall response rate 
a TS indication 
b Hodgkin lymphoma indication 
c Systemic anaplastic large cell lymphoma indication 
d Renal angiomyolipoma and TSC indication 
ALK+: anaplastic lymphoma kinase positive; ALL: acute lymphoblastic leukemia; ASCT: autologous stem cell transplant; AP: accelerated phase; BP: blast phase; CI: confidence 
interval; CLL: chronic lymphocytic leukemia; CML: chronic myeloid leukemia; CP: chronic phase; FEC: fluorouracil, epirubicin, and cyclophosphamide; HER2: human epidermal 
growth factor; HR: hazard ratio; MDR: multi-drug resistant; NSCLC: non-small cell lung cancer; PFS: progression-free survival; Ph+: Philadelphia chromosome positive; Ph-: 
Philadelphia chromosome negative; PTCL: peripheral T-cell lymphoma; SEGA: subependymal giant cell astrocytoma; TB: tuberculosis; TCH: docetaxel, carboplatin, and 
trastuzumab; TS: tuberous sclerosis; TKI: tyrosine kinase inhibitor; TSC: tuberous sclerosis complex.  
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Table 3. Characteristics and findings of completed and published post-approval, confirmatory studies of drugs receiving Accelerated Approval.  
Agent Participant 
population 
Design Comparators Enrollment Primary 
endpoint 
Magnitude of benefitc 
Bevacizumab Newly diagnosed 
glioblastoma e1 
Double-blind, 
placebo-
controlled 
randomized trial 
Arm 1: bevacizumab + 
radiotherapy-temozolomide  
Arm 2:  placebo + 
radiotherapy-temozolomide 
921 PFS and overall 
survival (co-
primary 
endpoints) 
Median PFS 
Arm 1: 10.6 months 
Arm 2: 6.2 months  
HR: 0.64, 95% CI: 0.55-0.74, p<0.001 
Median overall survival 
Arm 1: 16.8 months  
Arm 2: 16.7 months  
HR: 0.88, 95% CI: 0.76-1.02, p=0.10 
Ofatumumab Untreated patients 
with CLL e2 
Add-on 
comparator, 
open-label 
randomized trial 
Arm 1: ofatumumab + 
chlorambucil  
Arm 2: chrorambucil 
447 PFS Arm 1: 22.4 months  
Arm 2: 13.1 months  
HR: 0.57, 95% CI: 0.45-0.72, p<0.0001 
Lapatinib HER2-positive 
metastatic breast 
cancer e3 
Active-
comparator, 
open-label 
randomized trial 
Arm 1: lapatinib + taxane  
Arm 2: trastuzumab + taxane 
652 PFS Arm 1: 9.0 months  
Arm 2: 11.3 months  
HR: 1.33, 95% CI: 1.06-1.67, p=0.01 
More deaths occurred with lapatinib compared to 
trastuzumab: 102 vs. 82  
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HR: 1.28, 95% CI: 0.95-1.72, p=0.11 
Nilotinib Newly diagnosed 
CP CML e4 
Active-
comparator, 
open-label 
randomized trial 
 
Long-term extension 
of pre-approval study 
Arm 1: nilotinib 300 mg twice 
daily 
Arm 2: nilotinib 400 mg twice 
daily 
Arm 2: imatinib 400 mg once 
daily 
846 Major molecular 
response 
Arm 1: 217 (77.0%)  
Arm 2: 217 (77.2%) 
Arm 3: 171 (60.4%) 
 
Dasatinib Newly diagnosed 
CP CML e5 
Active-
comparator, 
open-label 
randomized trial 
 
Long-term extension 
of pre-approval study 
Arm 1: dasatinib  
Arm 2: imatinib 
519 Complete 
cytogenetic 
response 
Arm 1: 28.0%  
Arm 2: 26.0%  
(frequency data not reported) 
Everolimusa 
 
TSC-related SEGA 
e6 
Single-arm 
extension of trial 
 
Long-term extension 
of pre-approval study 
None 111 Response 64 (57.7%) 
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TSC-related SEGA 
e7 
Single-arm trial None 27 Change in SEGA 
volume 
0.50 (range = −0.74 to 9.84) cm3 
Crizotinib 
 
Locally advanced 
or metastatic ALK-
positive lung cancer 
following one prior 
platinum-based 
regimen e8 
Active-
comparator, 
open-label 
randomized trial 
Arm 1: crizotinib  
Arm 2: chemotherapy 
(pemetrexed or docetaxel) 
347 PFS Arm 1: 7.7 months 
Arm 2: 3.0 months  
HR: 0.49, 95% CI: 0.37-0.64, p<0.001 
 Advanced ALK-
positive 
nonsquamous 
NSCLC without 
previous systemic 
treatment for 
advanced disease e9 
Active-
comparator, 
open-label 
randomized trial 
Arm 1: crizotinib  
Arm 2: chemotherapy 
(pemetrexed + cisplatin or 
carboplatin) 
343 PFS Arm 1: 10.9 months  
Arm 2: 7.0 months  
HR: 0.45, 95% CI: 0.35-0.60, p<0.001 
Everolimusb Renal 
angiomyolipoma 
and diagnosis of 
TSC  or LAM e10 
Single-arm 
extension of trial 
 
Long-term extension 
of pre-approval study 
None 112 Response 60 (54.0%) 
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Carfilzomib 
 
Relapsed multiple 
myeloma following 
one to three prior 
treatments e11 
Add-on 
comparator, 
open-label 
randomized trial 
Arm 1: carfilzomib + 
lenalidomide + dexamethasone  
Arm 2: lenalidomide + 
dexamethasone 
792 PFS Arm 1: 26.3 months  
Arm 2: 17.6 months  
HR: 0.69, 95% CI: 0.57-0.83, p=0.0001 
Relapsed or 
refractory multiple 
myeloma following 
one to three prior 
treatments e12 
Active-
comparator, 
open-label 
randomized trial 
Arm 1: carfilzomib + 
dexamethasone  
Arm 2:  bortezomib + 
dexamethasone 
929 PFS Arm 1: 18.7 months  
Arm 2: 9.4 months  
HR: 0.53, 95% CI: 0.44-0.64, p<0.0001 
Omacetaxine CML who had 
received 2 or more 
approved TKI 
therapy e13 
Post-hoc pooled 
analysis of 2 
single-arm trials 
 
Long-term extension 
of pre-approval study 
None 111 Major 
cytogenetic 
response and 
major 
hematologic 
response 
CP CML: 14 (18.0%)  
AP CML: 5 (14.0%)  
Ponatinib 
 
 
 
Newly diagnosed 
patients with CP 
CML previously 
untreated patients 
e14 
Active-
comparator, 
open-label 
randomized trial 
Arm 1: ponatinib  
Arm 2: imatinib 
307 
(22 remained on 
study at 12 
months had had 
a molecular 
Major molecular 
response 
 
 Arm 1: 8 (80.0%)  
Arm 2: 5 (38.0%)  
Trial was terminated early following concerns 
about vascular adverse events observed in patients 
given ponatinib in other trials 
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assessment) 
Healthy adults e15 Single-arm cross-
over study 
None 20 Pharmacokinetics Statistically significant interaction with rifampin 
Healthy adults e16 Single-arm cross-
over study 
None 20 Pharmacokinetics Modest reduction in ponatinib concentration 
CML and Ph+ 
ALL after prior 
therapy e17 
Single-arm trial 
 
Long-term extension 
of pre-approval study 
None 449 Major 
cytogenetic 
response and 
major 
hematologic 
response  
CP CML: 158 (59.0%)  
AP CML: 51 (61.0%)  
BP CML: 19 (31.0%)  
Ph+ ALL: 13 (41.0%) 
Ibrutinib Relapsed or 
refractory mantle 
cell lymphoma e18 
Single-arm trial 
 
Long-term extension 
of pre-approval study 
None 111 Overall response 
rate 
67.0% (frequency data not reported) 
a TS indication 
b Renal angiomyolipoma and TSC indication 
c As reported in primary analysis in publication 
ALK+: anaplastic lymphoma kinase positive; ALL: acute lymphoblastic leukemia; AP: accelerated phase; BP: blast phase; CI: confidence interval; CLL: chronic lymphocytic 
leukemia; CML: chronic myeloid leukemia; CP: chronic phase; FEC: fluorouracil, epirubicin, and cyclophosphamide; HER2: human epidermal growth factor; HR: hazard ratio; 
LAM: Lymphangioleimyomatosis; MDR: multi-drug resistant; NSCLC: non-small cell lung cancer; PFS: progression-free survival; Ph+: Philadelphia chromosome positive; Ph-: 
Philadelphia chromosome negative; PTCL: peripheral T-cell lymphoma; SEGA: subependymal giant cell astrocytoma; TB: tuberculosis; TCH: docetaxel, carboplatin, and 
trastuzumab; TS: tuberous sclerosis; TKI: tyrosine kinase inhibitor; TSC: tuberous sclerosis complex. 
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Table 4. Comparison of pre-approval and post-approval study characteristics. 
Characteristics Pre-approval 
studies 
(n=30) 
Post-approval 
studies 
(n=18) 
Difference in 
proportions  
(95% CI) 
P value 
for 
difference 
Enrollment, median (IQR) 132 (89-224) 345 (111-619) - 0.37 
Randomized, no. (%) 12 (40) 10 (56) 16 (-15 to 46) 0.31 
Includes comparator, no. (%) 11 (37) 10 (56) 19 (-11 to 49) 0.21 
Primary endpointa     
Disease response, no. (%) 21 (70) 9 (50) -20 (-49 to 9) 0.17 
Progression-free survival, no. (%) 1 (3) 7 (39) 36 (15 to 56) 0.001 
Overall survival, no. (%) 0 (0) 1* (6) 6 (0 to 142) 0.20 
Other, no. (%) 8 (27) 2 (11) -16 (-40 to 89) 0.21 
a Primary endpoints do not add up to total number of post-approval studies: one study included two primary endpoints. 
* Co-primary endpoint with progression-free survival.  
 
 
 
